Sanofi promises it's committed to Afrezza; Merck puts Gerberding in public health comms post; GSK files for new Volibris use;

> Sanofi ($SNY) Chairman Serge Weinberg assured Goldman Sachs analysts that the French drugmaker remains committed to launching and marketing MannKind's ($MNKD) new inhaled insulin product Afrezza. Report

> Merck ($MRK) tapped former CDC chief Julie Gerberding as its EVP for strategic communications, global public policy and population health, a new position; previously she headed up the company's vaccines unit. Report

> GlaxoSmithKline ($GSK) asked European regulators to expand use of its hypertension drug Volibris for use in combination therapy for pulmonary arterial hypertension patients. Report

> ViiV Healthcare asked Japanese regulators to approve its single pill HIV regimen Triumeq, comprising dolutegravir, abacavir and lamivudine; it won FDA approval in September. Report

> Lundbeck said the FDA is reviewing its request to allow its long-acting antipsychotic Abilify Maintena to be injected into the deltoid muscle. Report

And Finally... Merck KGaA's drug unit rolled out an iPhone app to allow patients to scan meds to make sure they're not counterfeit. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.

Analysts are cautiously optimistic Amgen's $13.4 billion purchase of Celgene's psoriasis blockbuster Otezla will pay off.